×
About 144 results

ALLMedicine™ Lung Cancer Biomarkers Center

Research & Reviews  61 results

Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic re...
https://doi.org/10.1016/j.critrevonc.2020.103037
Critical Reviews in Oncology/hematology; Janssens E, van Meerbeeck JP et. al.

Aug 10th, 2020 - Volatile organic compounds (VOCs) have shown potential as non-invasive breath biomarkers for lung cancer, but their unclear biological origin currently limits clinical applications. This systematic review explores headspace analysis of VOCs in pat...

Plasma RNA sequencing of extracellular RNAs reveals potential biomarkers for non-small ...
https://doi.org/10.1016/j.clinbiochem.2020.06.004
Clinical Biochemistry; Wang L, Wang J et. al.

Jun 11th, 2020 - Lung cancer is one of the most common malignancies, and it has extremely high incidence and mortality rates. Although there have been many studies focused on lung cancer biomarkers, few have reported the extracellular RNA profiles of lung cancer. ...

Reactive oxygen species-regulating proteins peroxiredoxin 2 and thioredoxin, and glycer...
https://doi.org/10.1097/CEJ.0000000000000537
European Journal of Cancer Prevention : the Official Jour... Rostila AM, Anttila SL et. al.

Sep 30th, 2019 - Lung cancer is a deadly disease, typically caused by known risk factors, such as tobacco smoke and asbestos exposure. By triggering cellular oxidative stress and altering the antioxidant pathways eliminating reactive oxygen species (ROS), tobacco ...

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1832
Kulasinghe,A.,et al

Nov 21st, 2018 - Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, tumors change dynamically in response to therapy, and there remains a need for a more representative biomarker that can be assayed over the course ...

Lung Cancer Biomarkers and Screening
https://clinicaltrials.gov/ct2/show/NCT00301119

Oct 18th, 2018 - OBJECTIVES: Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers. Identify preneoplastic cellular changes and lesions in these patients. OUTLINE: Participants are s...

see more →

Guidelines  7 results

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1832
Kulasinghe,A.,et al

Nov 21st, 2018 - Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, tumors change dynamically in response to therapy, and there remains a need for a more representative biomarker that can be assayed over the course ...

Molecular Testing for the Selection of Patients With Lung Cancer for Treatment With Targeted...
http://ascopubs.org/doi/full/10.1200/JCO.2017.76.7293
Gregory P. Kalemkerian

Mar 19th, 2018 - In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association forMolecular Pathology (AMP) recently updated their recommendations for molec.

New Strategies and Challenges in Lung Proteomics and Metabolomics
http://www.thoracic.org/statements/resources/research/strategies-challenges%20-lung-proteomics-and-metabolomics.pdf
Russell P. Bowler

Nov 30th, 2017 - This document presents the proceedings from the workshop entitled, "New Strategies and Challenges in Lung Proteomics and Metabolomics" held February 4th-5th, 2016, in Denver, Colorado. It was sponsored by the National Heart Lung Blood Institute, t.

IASLC Atlas of PD-L1 Testing in Lung Cancer
https://www.iaslc.org/publications/iaslc-atlas-pd-l1-testing-lung-cancer
IASLC

Sep 30th, 2017 - The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker ...
http://www.thoracic.org/statements/resources/lcod/molec-biomarkers-lung-cancer.pdf
Peter J. Mazzone

Sep 30th, 2017 - With a focus on the clinical applications of lung cancer screening and lung nodule evaluation, the policy statement outlines categories of results that should be reported in the early phases of molecular biomarker development, discusses the level.

see more →

Drugs  1 results see all →

Clinicaltrials.gov  73 results

Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic re...
https://doi.org/10.1016/j.critrevonc.2020.103037
Critical Reviews in Oncology/hematology; Janssens E, van Meerbeeck JP et. al.

Aug 10th, 2020 - Volatile organic compounds (VOCs) have shown potential as non-invasive breath biomarkers for lung cancer, but their unclear biological origin currently limits clinical applications. This systematic review explores headspace analysis of VOCs in pat...

Plasma RNA sequencing of extracellular RNAs reveals potential biomarkers for non-small ...
https://doi.org/10.1016/j.clinbiochem.2020.06.004
Clinical Biochemistry; Wang L, Wang J et. al.

Jun 11th, 2020 - Lung cancer is one of the most common malignancies, and it has extremely high incidence and mortality rates. Although there have been many studies focused on lung cancer biomarkers, few have reported the extracellular RNA profiles of lung cancer. ...

Reactive oxygen species-regulating proteins peroxiredoxin 2 and thioredoxin, and glycer...
https://doi.org/10.1097/CEJ.0000000000000537
European Journal of Cancer Prevention : the Official Jour... Rostila AM, Anttila SL et. al.

Sep 30th, 2019 - Lung cancer is a deadly disease, typically caused by known risk factors, such as tobacco smoke and asbestos exposure. By triggering cellular oxidative stress and altering the antioxidant pathways eliminating reactive oxygen species (ROS), tobacco ...

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1832
Kulasinghe,A.,et al

Nov 21st, 2018 - Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, tumors change dynamically in response to therapy, and there remains a need for a more representative biomarker that can be assayed over the course ...

Lung Cancer Biomarkers and Screening
https://clinicaltrials.gov/ct2/show/NCT00301119

Oct 18th, 2018 - OBJECTIVES: Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers. Identify preneoplastic cellular changes and lesions in these patients. OUTLINE: Participants are s...

see more →

News  2 results

The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1832
Kulasinghe,A.,et al

Nov 21st, 2018 - Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, tumors change dynamically in response to therapy, and there remains a need for a more representative biomarker that can be assayed over the course ...

Deciphering lung cancer biomarkers shrouded in tobacco smoke
https://www.mdedge.com/familymedicine/article/105905/lung-cancer/deciphering-lung-cancer-biomarkers-shrouded-tobacco-smoke/page/0/1
Family Practice News;

Jan 20th, 2016 - In addition, the exposure biomarkers are not entirely predictive and thus, will need to be combined with multiple DNA adducts and repair if susceptible smokers are to be identified and targeted for state-of-the art cessation approaches and surveil.

see more →